UBS Asset Management Americas Inc. boosted its stake in shares of Masimo Co. (NASDAQ:MASI) by 11.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 63,588 shares of the medical equipment provider’s stock after buying an additional 6,711 shares during the period. UBS Asset Management Americas Inc. owned approximately 0.12% of Masimo worth $5,392,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the stock. Schroder Investment Management Group increased its holdings in shares of Masimo by 38.4% in the 4th quarter. Schroder Investment Management Group now owns 468,020 shares of the medical equipment provider’s stock worth $39,687,000 after purchasing an additional 129,905 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Masimo by 26.5% in the 4th quarter. Arizona State Retirement System now owns 34,216 shares of the medical equipment provider’s stock worth $2,902,000 after buying an additional 7,162 shares during the last quarter. Eagle Asset Management Inc. boosted its stake in shares of Masimo by 2.8% in the 4th quarter. Eagle Asset Management Inc. now owns 33,704 shares of the medical equipment provider’s stock worth $2,858,000 after buying an additional 932 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Masimo by 8.5% in the 4th quarter. The Manufacturers Life Insurance Company now owns 111,556 shares of the medical equipment provider’s stock worth $9,459,000 after buying an additional 8,725 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of Masimo by 60.8% in the 4th quarter. Wells Fargo & Company MN now owns 247,347 shares of the medical equipment provider’s stock worth $20,974,000 after buying an additional 93,506 shares during the last quarter. 82.74% of the stock is owned by institutional investors.
In other news, Director Sanford Fitch sold 2,000 shares of Masimo stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $90.00, for a total value of $180,000.00. Following the sale, the director now directly owns 70,249 shares of the company’s stock, valued at $6,322,410. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Yongsam Lee sold 10,000 shares of Masimo stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $88.17, for a total value of $881,700.00. Following the completion of the sale, the executive vice president now directly owns 75,018 shares in the company, valued at $6,614,337.06. The disclosure for this sale can be found here. Insiders sold 24,100 shares of company stock worth $2,186,340 over the last 90 days. Company insiders own 13.10% of the company’s stock.
Masimo stock opened at $86.21 on Monday. The firm has a market capitalization of $4,489.78, a price-to-earnings ratio of 30.83, a P/E/G ratio of 2.28 and a beta of 0.92. Masimo Co. has a 52-week low of $80.69 and a 52-week high of $104.71.
Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $0.72 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.11. Masimo had a return on equity of 22.75% and a net margin of 16.49%. The business had revenue of $225.20 million for the quarter, compared to the consensus estimate of $201.54 million. During the same period in the previous year, the business earned $0.46 earnings per share. The business’s revenue was up 22.9% on a year-over-year basis. analysts expect that Masimo Co. will post 2.81 EPS for the current fiscal year.
MASI has been the topic of a number of research reports. Zacks Investment Research downgraded Masimo from a “buy” rating to a “hold” rating in a research note on Wednesday, February 7th. Barclays initiated coverage on Masimo in a research note on Friday, March 9th. They issued an “overweight” rating and a $97.00 price target on the stock. BidaskClub downgraded Masimo from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. Finally, Piper Jaffray Companies reiterated a “hold” rating and set a $91.00 target price on shares of Masimo in a research report on Thursday, March 1st. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $101.00.
ILLEGAL ACTIVITY WARNING: “UBS Asset Management Americas Inc. Has $5.39 Million Holdings in Masimo Co. (NASDAQ:MASI)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/19/ubs-asset-management-americas-inc-has-5-39-million-position-in-masimo-co-masi.html.
Masimo Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.